Ovid Therapeutics
United States · Biotechnology, Healthcare, Health Care
Ovid Therapeutics is a biopharmaceutical company striving to calm the storm that causes seizures by developing new medicines for epilepsies and brain conditions. For those who need relief, we must succeed—their hopes are our aspirations. We act with urgency, ingenuity and integrity as we seek a future free of seizures. At Ovid, we are pursuing small molecule compounds with untapped potential.
Key facts
- Headquarters
- United States
- Employees
- 23
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (OVID)
- Website
- ovidrx.com
- Company page
Recent activity at Ovid Therapeutics
- : Ovid Therapeutics Inc. Appoints Kevin Norrett as Chief Business Officer and Promotes Charles Carter to CFO
- : Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
- : SEC 8-K (5.02): On May 29, 2026, Ovid Therapeutics Inc.'s Board of Directors approved an increase in the size of the Board, effective June 15, 2026, and appointed Dr. Anna Greka as a Class III director. Her term will conclude at the 2029 annual meeting of stockholders. Following this appointment, the Board will consist of seven directors. Dr. Greka, currently a Professor of Medicine, will also serve on the Compensation Committee and Science and Technology Committee, indicating a strategic move to enhance governance and oversight within the company. This change reflects the company's ongoing efforts to bolster its leadership team and governance structure.
- : SEC 8-K (8.01): On April 17, 2026, Ovid Therapeutics Inc. reported the expiration of its Series A Warrants issued during an October 2025 private placement. A total of 38,481,325 common shares were underlying these warrants, of which investors exercised 33,597,860 shares at $1.40 per share and 4,883,464 pre-funded warrants at $1.399 per share. This transaction resulted in gross proceeds of approximately $53.9 million for the Company. The exercise of the warrants reflects investor confidence and provides significant capital to support Ovid Therapeutics' ongoing operations and strategic objectives.
- : SEC 8-K (1.01): On March 17, 2026, Ovid Therapeutics Inc. entered into a Securities Purchase Agreement to issue and sell a total of 19,154,321 shares of its common stock at $2.01 per share, along with pre-funded warrants to purchase up to 10,701,710 additional shares at $2.009 per warrant. This agreement constitutes a private placement financing (PIPE), allowing the company to raise significant capital. Each pre-funded warrant has an exercise price of $0.001 and is immediately exercisable, which provides flexibility and potential liquidity for the investors. This strategic financing is aimed at enhancing the company's financial position and supporting its ongoing projects.
- : SEC 8-K (5.07): On December 11, 2025, Ovid Therapeutics Inc. conducted a special meeting of stockholders where various proposals were voted on. As of the record date, October 31, 2025, the company had 71,212,353 shares of common stock outstanding, with 38,044,680 shares (approximately 53.42%) present to constitute a quorum for the meeting. The specifics of the proposals and voting results were referenced, with further details provided in a definitive proxy statement filed on November 7, 2025. This meeting and the outcomes may have strategic implications for company governance and future decision-making processes.
- : Ovid Therapeutics Inc.
- : Ovid Therapeutics Inc.
Ovid Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Jan 2017 | Venture | $25.9M |
| Aug 2015 | Venture | $75.0M |
Leadership
- Karen Bernstein, Director
- Douglas Williams, Director
- Bart Friedman, Director
- Jeremy Levin, Executive Officer, Director
- Matthew During, Executive Officer, Director
- Charles Carter, Chief Financial Officer
- Kevin Norrett, Chief Business Officer
- Barbara Salzmann, Medizinischer Kosmetiker
- Harish Vasudevan, Associate Director, Program Management and Leadership
- Jatinder Singh, Senior Research Fellow
- Naomi Shaw, Senior Director, Accounting
- Simon Kelner, Senior Advisor
Verified email and direct lines for Ovid Therapeutics’s decision-makers are on Fundz. See plans
Employee benefit plans
Ovid Therapeutics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Ovid Therapeutics in the news
- Ovid Therapeutics to Participate in Upcoming Investor Conferences - globenewswire.com (Sep 03, 2026)
- Ovid Therapeutics to Participate in Upcoming Investor Conferences - globenewswire.com (Jun 04, 2026)
- GABA-AT Inhibitor OV329 Shows Safety, Preliminary Target Engagement in Phase 1 Study - NeurologyLive (Dec 08, 2025)
- Ovid Therapeutics Inc. (OVID) Company Profile & Facts - Yahoo Finance (May 12, 2017)
- Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results - globenewswire.com (May 12, 2026)
- Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds - globenewswire.com (Oct 03, 2025)
- Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results - globenewswire.com (Aug 13, 2026)
- Ovid Therapeutics Strengthens Executive Leadership Team to - globenewswire.com (Jul 08, 2026)
Companies similar to Ovid Therapeutics
- Oncotelic Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
- Tempest Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
- BiomX · Biotechnology, Healthcare, Health Care, Therapeutics
- BioLineRx Ltd · Biotechnology, Healthcare, Health Care, Therapeutics
- Galecto · Biotechnology, Healthcare, Health Care, Therapeutics
About Ovid Therapeutics: questions and answers
What does Ovid Therapeutics do?
Ovid Therapeutics is a biopharmaceutical company striving to calm the storm that causes seizures by developing new medicines for epilepsies and brain conditions. For those who need relief, we must succeed—their hopes are our aspirations. We act with urgency, ingenuity and integrity as we seek a future free of seizures. At Ovid, we are pursuing small molecule compounds with untapped potential.
Where is Ovid Therapeutics headquartered?
Ovid Therapeutics is headquartered in United States.
How many employees does Ovid Therapeutics have?
Ovid Therapeutics has about 23 employees.
Has Ovid Therapeutics raised funding?
Yes. Fundz has recorded 2 funding events for Ovid Therapeutics. The most recent, $25.9M, was in Jan 2017.
What is the latest news on Ovid Therapeutics?
On Jul 14, 2026, Ovid Therapeutics Inc. Appoints Kevin Norrett as Chief Business Officer and Promotes Charles Carter to CFO
Is Ovid Therapeutics a public company?
Yes. Ovid Therapeutics is publicly traded under the ticker OVID.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy